Infosys has announced a definitive agreement to acquire BASE life science, a European technology and consulting firm in the life sciences industry. The acquisition reaffirms Infosys commitment to help global life sciences companies realise business value from cloud-first digital platforms and data, to speed-up clinical trials and scale drug development.
Ravi Kumar, president, Infosys, said, ‘This acquisition augments Infosys' deep life sciences expertise, and expands our footprint further in the Nordics region and across Europe, and scales our digital transformation capabilities with cloud-based industry solutions. We are excited to welcome BASE life science and its leadership team into the Infosys family.’
Martin Woergaard, CEO, BASE life science added: ‘Over the last five years, BASE life science has delivered tremendous growth, and created a stellar life sciences consulting firm in Europe. With Infosys as our catalyst, we will be able to accelerate our expansion internationally and create development opportunities for our people. Infosys is a solid, global technology leader, that is a perfect match for ensuring continuous success of BASE while sharing our common purpose and values.’
The acquisition is expected to close during the second quarter of fiscal 2023, subject to customary closing conditions.
